Toxicology News and Research

Latest Toxicology News and Research

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.

22 Feb 2010

Major challenge facing today's toxicologists: Developing test systems to predict toxicity of compounds

Attagene Inc., a leader in developing innovative technologies for analyzing gene regulatory pathways, announced today the online publication of a paper in Chemical Research in Toxicology, a journal of the American Chemical Society, that highlights results of their collaborative work with the Environmental Protection Agency's National Center for Computational Toxicology (NCCT).

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

SRI International establishes new Neurodegenerative Diseases Research Program

SRI International, an independent nonprofit research and development institute, announced today that a new Neurodegenerative Diseases Research Program has been established within its Center for Health Sciences. This new SRI group of neuroscientists and researchers working at the cutting edge of science brings $6.2 million of funding from the National Institutes of Health (NIH), including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Environmental Health Sciences (NIEHS), and National Institute of General Medical Sciences (NIGMS).

19 Feb 2010

Group B streptococcus may have significant public health implications: Study

A common bacteria found in many healthy adult females that can cause life-threatening infections when passed to newborns could be introduced to some women through frequent contact with cows, according to a research team led by a Michigan State University pediatrician.

19 Feb 2010

BPA has no effects on brain development: New study

This new study, which exposed pregnant rodents to a range of BPA dietary doses from low to high, concluded that BPA had no effects on brain development or behavior in their offspring that had been exposed to BPA in utero and throughout development. The robust study was conducted by highly qualified researchers at WIL Research Laboratories.

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

BioMimetic Therapeutics annouces completion of Augment Bone Graft PMA submission

BioMimetic Therapeutics, Inc. today announced it has submitted the third and final module of its Premarket Approval (PMA) application for marketing of Augment™ Bone Graft in the U.S. This final module, containing a comprehensive review of the clinical data related to Augment, completes the PMA application to the FDA. The Company previously announced the filing of both the pre-clinical pharmacology/toxicology and quality/manufacturing modules with the FDA in June of 2009.

18 Feb 2010

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for drug dependence, smoking cessation and obesity, announced today that the company has retained Exponential Pharma Ventures LLC to assist in establishing a clinical development partnership for its cocaine dependence program with a fully integrated pharmaceutical company.

17 Feb 2010

Adding rosemary extracts in ground beef can reduce cancer-causing agents

The addition of rosemary extract to ground beef actually reduces cancer-causing agents that can form upon cooking, according to a recent study in the Journal of Food Science, published by the Institute of Food Technologists.

16 Feb 2010

Effects of eco-toxicology on Zebra fish

Rasoul Nourizadeh-Lillabadi has shown that zebra fish can be used as models in order to study the effects of eco-toxicology on fish indigenous to Norway. The toxic substances used in the research project come from water effluent from the offshore industry and from organic material that had accumulated in the liver of burbot fish in the lakes of Mjøsa and Losna.

16 Feb 2010

Albemarle, Pharmacore partner to provide manufacturing capabilities for high volume capacity projects

Albemarle Corporation, a leading global provider of custom manufacturing services, announced today it will partner with PharmaCore to provide manufacturing capabilities for customers with projects that require high volume capacity.

16 Feb 2010

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

The California Environmental Protection Agency signaled intent to add bisphenol A (BPA) to the state's list of chemicals known to cause cancer or birth defects, adding to evidence the chemical should be banned from food and beverage containers.

12 Feb 2010

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.

11 Feb 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today its execution of a purchase agreement to acquire the Discovery and Preclinical business of MDS Pharma Services with facilities in Bothell, Washington; Lyon, France; and Taipei, Taiwan. Company headquarters will remain in Concord, Ohio.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Alcohol and energy drinks may create a dangerous mix

Energy drinks, favored among young people for the beverages' caffeine jolt, also play a lead role in several popular alcoholic drinks, such as Red Bull and vodka. But combining alcohol and energy drinks may create a dangerous mix, according to University of Florida research.

10 Feb 2010

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Silence Therapeutics plc today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. Known as PKN-3, the target is a protein kinase C-related molecule that is believed to play an important role in the growth of cancer cells, as well as metastasis formation.

8 Feb 2010

Toxicology News and Research

Latest Toxicology News and Research

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

Major challenge facing today's toxicologists: Developing test systems to predict toxicity of compounds

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

SRI International establishes new Neurodegenerative Diseases Research Program

Group B streptococcus may have significant public health implications: Study

BPA has no effects on brain development: New study

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

BioMimetic Therapeutics annouces completion of Augment Bone Graft PMA submission

Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program

Adding rosemary extracts in ground beef can reduce cancer-causing agents

Effects of eco-toxicology on Zebra fish

Albemarle, Pharmacore partner to provide manufacturing capabilities for high volume capacity projects

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Alcohol and energy drinks may create a dangerous mix

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Toxicology News and Research

Latest Toxicology News and Research

Forensics And Toxicology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in